PanTher Therapeutics Announces Agreement with MD Anderson Cancer Center and Appointment of Senior Clinical Advisor

PanTher Therapeutics, the biotech company developing drug-delivery platforms for unresectable, locally advanced solid tumors, today announced an agreement with The University of Texas MD Anderson Cancer Center and the appointment of a new senior clinical advisor. The collaboration will support preclinical testing of PanTher’s lead product for pancreatic cancer, PTM-101, and is intended to demonstrate readiness for future human clinical trials.